Back to Search Start Over

All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.

Authors :
Xu LW
Su YZ
Tao HF
Source :
Current medical science [Curr Med Sci] 2021 Jun; Vol. 41 (3), pp. 491-497. Date of Electronic Publication: 2021 Jun 25.
Publication Year :
2021

Abstract

All-trans retinoic acid (ATRA) and pre-upfront arsenic trioxide (ATO) have revolutionized the therapy of acute promyelocytic leukemia (APL). However, internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD) mutations is associated with increased risk of relapse. The aim of this study was to analyze the prognostic impact of FLT3-ITD on APL patients who received remission induction with ATRA, idarubicin (IDA) and/or ATO, followed by ATRA plus ATO along with anthracycline, as consolidation therapy. A total of 72 patients newly diagnosed with APL were included in this study. 83.3% of the patients achieved complete remission (CR) after induction therapy. FLT3-ITD mutations were detected in 16 (22.2%) patients and closely related to bcr-3 PML-RARa transcript (P<0.001). The 5-year overall survival (OS) rate was 100% in both FLT3-ITD <superscript>positive</superscript> and FLT3-ITD <superscript>negative</superscript> groups, and there was no significant difference in 5-year event-free survival (EFS) between the two groups (78.3% vs. 83.3%, P=0.85). ATRA plus ATO and anthracycline-based chemotherapy achieved great outcome in newly diagnosed APL regardless of the FLT3-ITD mutation status.<br /> (© 2021. Huazhong University of Science and Technology.)

Details

Language :
English
ISSN :
2523-899X
Volume :
41
Issue :
3
Database :
MEDLINE
Journal :
Current medical science
Publication Type :
Academic Journal
Accession number :
34169421
Full Text :
https://doi.org/10.1007/s11596-021-2377-3